Number of subjects reporting and number of reported TEAEs by SOC and PT
| MedDRA* description | rhNGF 20 µg/mL N=20 n (%) (n AE) | rhNGF 4 µg/mL N=20 n (%) (n AE) | Overall N=40 n (%) (n AE) | |||
| SOC | AEs n | Subjects n (%) | AEs n | Subjects n (%) | AEs n | Subjects n (%) |
| PT | ||||||
| All SOCs | 36 | 14 (70%) | 65 | 15 (75%) | 101 | 29 (72.5%) |
| Eye disorders | 32 | 12 (60%) | 46 | 15 (75%) | 78 | 27(67.5%) |
| Abnormal sensation in eye | 4 | 4 (20%) | 9 | 8 (40%) | 13 | 12 (30%) |
| Eye pain | 7 | 5 (25%) | 7 | 6 (30%) | 14 | 11 (27.5%) |
| Eye irritation | 6 | 3 (15%) | 7 | 7 (35%) | 13 | 10 (25%) |
| Eye pruritus | 4 | 2 (10%) | 5 | 5 (25%) | 9 | 7 (17.5%) |
| Vision blurred | 4 | 3 (15%) | 2 | 2 (10%) | 6 | 5 (12.5%) |
| Foreign body sensation in eyes | 0 | 0 | 4 | 4 (20%) | 4 | 4 (10%) |
| Photophobia | 2 | 1 (5%) | 3 | 3 (15%) | 5 | 4 (10%) |
| Lacrimation increased | 0 | 0 | 3 | 3 (15%) | 3 | 3 (7.5%) |
| Visual impairment | 1 | 1 (5%) | 1 | 1 (5%) | 2 | 2 (5%) |
| Asthenopia | 1 | 1 (5%) | 0 | 0 | 1 | 1 (2.5%) |
| Erythema of eyelid | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Eye discharge | 1 | 1 (5%) | 0 | 0 | 1 | 1 (2.5%) |
| Eye disorder | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Eyelid pain | 1 | 1 (5%) | 0 | 0 | 1 | 1 (2.5%) |
| Eyelid sensory disorder | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Ocular discomfort | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Ocular hyperaemia | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Vitreous detachment | 1 | 1 (5%) | 0 | 0 | 1 | 1 (2.5%) |
| Infections and infestations | 2 | 2 (10%) | 5 | 5 (25%) | 7 | 7 (17.5%) |
| Rhinitis | 0 | 0 | 2 | 2 (10%) | 2 | 2 (5%) |
| Conjunctivitis bacterial | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Herpes simplex | 1 | 1 (5%) | 0 | 0 | 1 | 1 (2.5%) |
| Nasopharyngitis | 1 | 1 (5%) | 0 | 0 | 1 | 1 (2.5%) |
| Sinusitis | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Urinary tract infection | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Nervous system disorders | 1 | 1 (5%) | 9 | 5 (25%) | 10 | 6 (15%) |
| Headache | 0 | 0 | 9 | 5 (25%) | 9 | 5 (12.5%) |
| Migraine | 1 | 1 (5%) | 0 | 0 | 1 | 1 (2.5%) |
| Musculoskeletal and connective tissue disorders | 0 | 0 | 2 | 2 (10%) | 2 | 2 (5%) |
| Back pain | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Neck pain | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Ear and labyrinth disorders | 1 | 1 (5%) | 0 | 0 | 1 | 1 (2.5%) |
| Tinnitus | 1 | 1 (5%) | 0 | 0 | 1 | 1 (2.5%) |
| Gastrointestinal disorders | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Flatulence | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Injury, poisoning and procedural complications | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Concussion | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
| Fall | 0 | 0 | 1 | 1 (5%) | 1 | 1 (2.5%) |
AE, adverse events; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; SOC, system organ class; TEAEs, treatment-emerged adverse events.